Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry
- Authors
- Hahn, JY[Hahn, Joo-Yong]; Song, YB[Song, Young-Bin]; Choi, JH[Choi, Jin-Ho]; Choi, SH[Choi, Sung-Hyuk]; Lee, SY[Lee, Sung Yun]; Park, HS[Park, Hun Sik]; Hur, SH[Hur, Seung Ho]; Lee, S[Lee, Sahng]; Han, KR[Han, Kyoo-Rok]; Rha, SW[Rha, Seung-Woon]; Cho, BR[Cho, Byung Ryul]; Park, JS[Park, Jong-Sun]; Yoon, J[Yoon, Junghan]; Lim, DS[Lim, Do Sun]; Lee, SH[Lee, Sang Hoon]; Gwon, HC[Gwon, Hyeon-Cheol]
- Issue Date
- Nov-2010
- Publisher
- JAPANESE CIRCULATION SOC
- Keywords
- Antiplatelets; Drug-eluting stents
- Citation
- CIRCULATION JOURNAL, v.74, no.11, pp.2314 - 2321
- Indexed
- SCIE
SCOPUS
- Journal Title
- CIRCULATION JOURNAL
- Volume
- 74
- Number
- 11
- Start Page
- 2314
- End Page
- 2321
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/73017
- DOI
- 10.1253/circj.CJ-10-0347
- ISSN
- 1346-9843
- Abstract
- Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients. (Circ J 2010; 74: 2314-2321)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/73017)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.